Navigation Links
Genomic analysis of prostate cancer indicates best course of action after surgery
Date:7/29/2014

(PHILADELPHIA) There is controversy over how best to treat patients after they've undergone surgery for prostate cancer. Does one wait until the cancer comes back or provide men with additional radiation therapy to prevent cancer recurrence? Now, a new study from Thomas Jefferson University shows that a genomic tool can help doctors and patients make a more informed decision.

"We are moving away from treating everyone the same," says first author Robert Den, M.D., Assistant Professor of Radiation Oncology and Cancer Biology at Thomas Jefferson University. "Genomic tools are letting us gauge which cancers are more aggressive and should be treated earlier with radiation, and which ones are unlikely to benefit from additional therapy."

Although surgery for prostate cancer is meant to be curative, in some men, the cancer can regrow. Doctors have developed high risk criteria based on clinical factors, but these criteria are imperfect predictors of cancer returning, or recurrence. Only about 50 percent of high risk patients ever go on to develop metastases, raising the question of whether those who receive additional therapy are being overtreated.

In an attempt to better understand how to treat their patient population, researchers led by Drs. Den and Adam Dicker, M.D., Ph.D., Chairman of the Department of Radiation Oncology at Jefferson, together with other members of the Kimmel Cancer Center Genitourinary team including Dr. Leonard Gomella, Chairman of the Department of Urology, assessed whether a genomic test designed to predict prostate cancer metastasis could also predict which patients would most benefit from radiation treatment after surgery.

The test, called Decipher, from the genome diagnostics company GenomeDx, generates a gene signature from a patient's cancer tissue sample. Based on this signature, the test stratifies patients into high, intermediate and low risk for cancer recurrence and metastases.

The researchers tested the genomes from tumor samples of 139 patients who had received radiation therapy following prostate surgery at Jefferson. Using medical records, the researchers grouped the patients by the treatments they received after surgery, and matched their records to the results of the genomic analysis.

The genomic analysis correctly predicted outcomes. The patients with a high Decipher score were more likely to develop metastases than those with a low score. In addition, those with a high Decipher score who received radiation earlier had longer survival than those who did not receive radiation immediately after surgery. The results showed that patients treated with radiation after surgery maintained low PSA levels for twice as long than those who were not treated with radiation.

"Our analysis suggests that genomic analysis scores could be used, in concert with other diagnostic measures such as PSA testing, to help determine which patients would benefit from additional radiation therapy and more aggressive measures, and which are less likely to benefit," says Dr. Den.


'/>"/>

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Following the genomic pathways to stop the spread of cancer
2. Genomic study of rare childrens cancer yields possible prognostic tool
3. Mayo, UCSF team discovers genomic variant that increases risk of brain tumors
4. Study identifies genes associated with genomic expansions that cause disease
5. $8.9 million NIH grant to study genomic link to premature heart disease
6. Edith Sanford Breast Cancer Foundation and TSRI partner in genomic breast cancer research
7. Molecular Genetics & Genomic Medicine: New open access journal launched by Wiley
8. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
9. Study shows large-scale genomic testing feasible, impacts therapy
10. Stanford/Yale study gives insight into subtle genomic differences among our own cells
11. NIH grant moves pathologists to the forefront of genomic medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... ... San Francisco dentist, Dr. Ben Amini , the founder at CitiDent, ... capable of taking digital impressions of teeth and gums. Conventional bite impressions have lagged ... , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are being ...
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s ... the field of midmarket financial software. , Members of the VAR Stars were selected ... based on revenue and those firms chosen represent a wide range of size and ...
(Date:1/15/2017)... , ... January 15, 2017 , ... ... Community Outreach is a program that strives to better communities around the world ... locations’ community. It also provides the opportunity for team members to become involved ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation ... achieved accreditation for its specialty care services. Albertsons Companies is the largest ... care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication ...
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco ... eight Bay Area counties for 2017. Almost 1,000 nominations were submitted and a ... award process. Results were announced the magazine’s January 2017 issue . , ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... PORTLAND, Oregon and PUNE, India ... According to a new report published by Allied Market ... Global Opportunity Analysis and Industry Forecast, 2014-2022," the ... million by 2022, from $5,768 million in 2015, growing ... The chemical & gas sterilization segment dominated the market ...
(Date:1/16/2017)... Bill is an internationally experienced medical device industry executive ... with global medical device companies, including Smith & Nephew, Angiodynamics, Orthovita ... products and building successful businesses in the sector and has worked ... and North America . ... Educated at the University of Edinburgh (Dental ...
(Date:1/16/2017)... 2017 CBDRx, the world,s premiere nutraceutical hemp ... rich hemp extract to Veteran,s groups across the country. ... hemp extract to Veteran,s groups across the United States.  ... in the world and through their passion, CBDRx honors ... phyto-nutrient rich hemp extract available. ...
Breaking Medicine Technology: